FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083062016> ?p ?o ?g. }

• W3083062016 endingPage "8363" @default.
• W3083062016 startingPage "8355" @default.
• W3083062016 abstract "Abstract Radiotherapy plus immune checkpoint inhibitors can potentially induce synergistic antitumor immune responses. However, little clinical evidence is established regarding their combination therapy. Here, we aimed to assess whether radiotherapy to the primary tumor impacts on the efficacy of pembrolizumab in advanced urothelial cancer. We retrospectively reviewed 98 advanced urothelial cancer patients receiving pembrolizumab in a second‐ or later‐line setting using our multicenter cohort. Patients were categorized according to a history of radiotherapy to the primary tumor: patients previously exposed to radiotherapy to the primary tumor (Radiotherapy group, 17 patients [17%]) and those not (Nonradiotherapy group, 81 patients [83%]). The associations of radiotherapy to the primary tumor with objective response and survival were evaluated. The Radiotherapy group showed a significantly higher objective response ratio than did the Non‐radiotherapy group (65% vs 19%; P < .001). The Radiotherapy group had a higher progression‐free survival rate compared with the Nonradiotherapy group (52% vs 28% at 12 months; P = .078), but statistical significance was not reached. The Radiotherapy group had a significantly higher overall survival rate compared with the Non‐radiotherapy group (77% vs 50% at 12 months; P = .025). From multivariate analysis, radiotherapy to the primary tumor was an independent predictor for longer overall survival (hazard ratio, 0.31; P = .032) along with Eastern Cooperative Oncology Group performance status ≤1 and the absence of visceral metastasis. Therefore, radiotherapy to the primary tumor may enhance the efficacy of pembrolizumab for patients with advanced urothelial cancer." @default.
• W3083062016 created "2020-09-11" @default.
• W3083062016 creator A5001530671 @default.
• W3083062016 creator A5006217384 @default.
• W3083062016 creator A5014625956 @default.
• W3083062016 creator A5030126202 @default.
• W3083062016 creator A5032348337 @default.
• W3083062016 creator A5038638440 @default.
• W3083062016 creator A5039314030 @default.
• W3083062016 creator A5044378194 @default.
• W3083062016 creator A5047164614 @default.
• W3083062016 creator A5048350768 @default.
• W3083062016 creator A5048923727 @default.
• W3083062016 creator A5051150655 @default.
• W3083062016 creator A5060240988 @default.
• W3083062016 creator A5074658156 @default.
• W3083062016 creator A5079626310 @default.
• W3083062016 creator A5081085839 @default.
• W3083062016 creator A5089375452 @default.
• W3083062016 creator A5089503656 @default.
• W3083062016 creator A5090215162 @default.
• W3083062016 date "2020-09-04" @default.
• W3083062016 modified "2023-09-27" @default.
• W3083062016 title "Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study" @default.
• W3083062016 cites W1890550626 @default.
• W3083062016 cites W1994826332 @default.
• W3083062016 cites W2017629237 @default.
• W3083062016 cites W2019607817 @default.
• W3083062016 cites W2079315541 @default.
• W3083062016 cites W2132379894 @default.
• W3083062016 cites W2159094759 @default.
• W3083062016 cites W2168847820 @default.
• W3083062016 cites W2269750828 @default.
• W3083062016 cites W2571353830 @default.
• W3083062016 cites W2588916311 @default.
• W3083062016 cites W2592144107 @default.
• W3083062016 cites W2618641368 @default.
• W3083062016 cites W2763053634 @default.
• W3083062016 cites W2771637939 @default.
• W3083062016 cites W2806383117 @default.
• W3083062016 cites W2811259712 @default.
• W3083062016 cites W2915288869 @default.
• W3083062016 cites W2944687997 @default.
• W3083062016 cites W2955294253 @default.
• W3083062016 cites W2972656409 @default.
• W3083062016 cites W2974766534 @default.
• W3083062016 cites W2998719569 @default.
• W3083062016 doi "https://doi.org/10.1002/cam4.3445" @default.
• W3083062016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7666746" @default.
• W3083062016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32886446" @default.
• W3083062016 hasPublicationYear "2020" @default.
• W3083062016 type Work @default.
• W3083062016 sameAs 3083062016 @default.
• W3083062016 citedByCount "7" @default.
• W3083062016 countsByYear W30830620162021 @default.
• W3083062016 countsByYear W30830620162022 @default.
• W3083062016 crossrefType "journal-article" @default.
• W3083062016 hasAuthorship W3083062016A5001530671 @default.
• W3083062016 hasAuthorship W3083062016A5006217384 @default.
• W3083062016 hasAuthorship W3083062016A5014625956 @default.
• W3083062016 hasAuthorship W3083062016A5030126202 @default.
• W3083062016 hasAuthorship W3083062016A5032348337 @default.
• W3083062016 hasAuthorship W3083062016A5038638440 @default.
• W3083062016 hasAuthorship W3083062016A5039314030 @default.
• W3083062016 hasAuthorship W3083062016A5044378194 @default.
• W3083062016 hasAuthorship W3083062016A5047164614 @default.
• W3083062016 hasAuthorship W3083062016A5048350768 @default.
• W3083062016 hasAuthorship W3083062016A5048923727 @default.
• W3083062016 hasAuthorship W3083062016A5051150655 @default.
• W3083062016 hasAuthorship W3083062016A5060240988 @default.
• W3083062016 hasAuthorship W3083062016A5074658156 @default.
• W3083062016 hasAuthorship W3083062016A5079626310 @default.
• W3083062016 hasAuthorship W3083062016A5081085839 @default.
• W3083062016 hasAuthorship W3083062016A5089375452 @default.
• W3083062016 hasAuthorship W3083062016A5089503656 @default.
• W3083062016 hasAuthorship W3083062016A5090215162 @default.
• W3083062016 hasBestOaLocation W30830620161 @default.
• W3083062016 hasConcept C121608353 @default.
• W3083062016 hasConcept C126322002 @default.
• W3083062016 hasConcept C143998085 @default.
• W3083062016 hasConcept C207103383 @default.
• W3083062016 hasConcept C2777701055 @default.
• W3083062016 hasConcept C2779013556 @default.
• W3083062016 hasConcept C2780057760 @default.
• W3083062016 hasConcept C2780283643 @default.
• W3083062016 hasConcept C44249647 @default.
• W3083062016 hasConcept C509974204 @default.
• W3083062016 hasConcept C71924100 @default.
• W3083062016 hasConceptScore W3083062016C121608353 @default.
• W3083062016 hasConceptScore W3083062016C126322002 @default.
• W3083062016 hasConceptScore W3083062016C143998085 @default.
• W3083062016 hasConceptScore W3083062016C207103383 @default.
• W3083062016 hasConceptScore W3083062016C2777701055 @default.
• W3083062016 hasConceptScore W3083062016C2779013556 @default.
• W3083062016 hasConceptScore W3083062016C2780057760 @default.
• W3083062016 hasConceptScore W3083062016C2780283643 @default.
• W3083062016 hasConceptScore W3083062016C44249647 @default.
• W3083062016 hasConceptScore W3083062016C509974204 @default.

• next